Loren Data's SAM Daily™

FBO DAILY ISSUE OF APRIL 03, 2003 FBO #0489
SOLICITATION NOTICE

66 -- Sequenom MassARRAY Point Instrument Upgrade

Notice Date

4/1/2003
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCi-30038-NG
 

Archive Date

5/1/2003
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI), Advanced Technology Center, (ATC), Core Genotyping Facility (CGF) plans to procure a Sequenom MassARRAY Point instrument on a sole source basis with Sequenom Inc., 3595 John Hopkins Court, San Diego, California, 92121. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. The National Cancer Institute (NCI) Core Genotyping Facility (CGF) is assessing human genetic variation, including Single Nucleotide Polymorphisms (SNPs) and other types of genetic variation (microsatellites, insertion/deletion mutations etc?), in a large number of separate population and family studies initiated by NCI investigators. Currently the CGF is utilizing four major technology platforms to assess human genetic variation: 1) TaqMan? Fluorescent 5' Nuclease cleavage, 2) Primer Extension detected by Matrix Assisted Laser Deionization/Adsorption - Time of Flight (MALDI-TOF), 3) Fluorescent DNA fragment analysis and sequencing detected by automated capillary electrophoresis systems, and 4) MGB Eclipse? 3' Hybridization Triggered Fluorescence. This instrument will be used in conjunction with the Sequenom MassARRAY MALDI_TOF system. The Sequenom MassARRAY system is a MALDI-TOF based system, which requires biological products to be placed on a small spot on a preformatted proprietary matrix Spectro-Chip made by Sequenom. This chip is then transferred to the mass spectrometer where the MALDI-TOF is determined. The CGF does currently have a 4 inkjet based Nanospotter which can provide the same task, but with much less accuracy and prescision, and use of this Nanospotter instrument has caused contamination problems using the homogenous Mass Extend Protocol. The CGF requires a high-throughput system designed for rapid dispensing of aqueous-based fluids in the submicroliter range. This rapid spotting must occur on a pre-defined "Spectro-CHIP" from a single 384 microtitre plate in ~ 12 minutes or less. The instrument must utilize a 6 x 4 pin array that endures thousands of spottings and unique pin design that utilizes non-contact sample transfer to preserve MALDI matrix. This instrument must also have an integrated sonicator and tip wash station removing the risk of contamination ensuring consistent sample transfer, and be able to ensure accurate spotting of every chip. The instrument must posses clear and easy-to-use software, which will minimize training and maximize technician efficiency. This instrument is necessary for the upgrade to an existing genotyping platform and will serve a critical role in the CGF's genotyping and assay development pipeline, necessary to perform contract genotyping for internal and external investigators. Sequenom Inc., is the only source known to the NCI that can meet the required specifications stated above. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. Capability statements and any other furnished information must be in writing and must contain sufficient material to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:00 PM EST (local Washington, DC time) on April 16, 2003. This action is pursuant to 41 USC 253 (1) and under the authority of FAR 6.302-1. If you have questions, please submit them in writing via electronic mail to Malinda Holdcraft at holdcram@exchange.nih.gov or via fax at 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purposes of determining whether to conduct a competitive requirement. No collect calls will be accepted. No faxed copies of capability statements will be accepted. No electronic copies of capability statements will be accepted. If interested in submitting a capability statement, please mail one (1) original and two (2) copies to: Malinda Holdcraft, NIH/NCI/RCB, 6120 Executive Blvd. Room 6072, Rockville, MD 20852-7194.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD 20892

Zip Code: 20892

Country: USA
 

Record

SN00292752-W 20030403/030401213343 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |